Efficacy of Naltrexone Treatment as Augmentation to SSRI in OCD Patients

This study has been completed.
Sponsor:
Information provided by:
Sheba Medical Center
ClinicalTrials.gov Identifier:
NCT00234689
First received: October 6, 2005
Last updated: January 28, 2008
Last verified: January 2008

October 6, 2005
January 28, 2008
January 2002
December 2004   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00234689 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Efficacy of Naltrexone Treatment as Augmentation to SSRI in OCD Patients
Not Provided

Assessing the efficacy of Naltrexone as augmentation to SSRI in patients with OCD

Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double-Blind
Obsessive Compulsive Disorder
Drug: Naltrexone
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
December 2004
December 2004   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of OCD
  • Treatment with SSRI for at least 10 weeks with no response

Exclusion Criteria:

  • Suffering from any medical condition
  • treatment with opiates
  • chronic use of drugs
  • Hepatitis or other liver related diseases
  • Incapability to sign an informed consent
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Israel
 
NCT00234689
SHEBA-99-1897-JZ-CTIL
Not Provided
Prof. Joseph Zohar, Chaim Sheba Medical Center
Sheba Medical Center
Not Provided
Principal Investigator: Joseph Zohar, MD Tel Aviv University
Study Chair: Revital Amiaz, MD Tel Aviv University
Sheba Medical Center
January 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP